Mechanistic description
Convergence hypothesis: PINK1/Parkin-mediated mitophagy dysfunction in neurons and TREM2-mediated microglial mitophagy failure represent a unified convergence point driving both Parkinson’s disease (PD) and Alzheimer’s disease (AD) pathophysiology.
PD-specific mechanism: PINK1 kinase phosphorylates Parkin (PRKN) and ubiquitin at mitochondrial outer membrane, triggering clearance of damaged mitochondria. In PD, mutations in PINK1 (PARK6) or PRKN (PARK2) impair this clearance, leading to mitochondrial ROS spillover that accelerates α-synuclein aggregation. The α-synuclein (SNCA) feedback loop then further inhibits mitochondrial complex I (NDUFS7), creating a vicious cycle.
AD-specific mechanism: TREM2 R47H/haploinsufficiency in AD reduces microglial mitophagic capacity, preventing clearance of mitochondrial debris from synapses. Accumulated mitochondrial damage elevates regional oxidative stress, which hyperphosphorylates tau (MAPT) via GSK3B activation and drives amyloid-beta (APP/ABCA1) aggregation. The tau feedback loop further suppresses complex I efficiency, creating a parallel vicious cycle.
Shared molecular targets (2+ per disease): • PINK1 (PD: mitophagy initiation) ↔ TREM2 (AD: microglial mitophagy) — both converge on mitochondrial quality control • PRKN/Parkin (PD) ↔ TREM2 downstream effectors including TYROBP/DAP12 (AD) — both signal through ubiquitin-like pathways • Mitochondrial complex I subunits (NDUFS7, MT-ND1 in PD; normalized via PGC1A/PPARG in AD) — shared oxidative phosphorylation disruption • STUB1/CHIP E3 ligase (observed in both: degrades phosphorylated tau in AD and Parkin substrates in PD)
Falsifiable predictions:
- In iPSC-derived microglia from TREM2 R47H AD patients, PINK1/PRKN knockdown will exacerbate mitophagy failure and increase intracellular Abeta42 more than either intervention alone (synergy prediction).
- Post-mortem PD substantia nigra and AD prefrontal cortex both show reduced Parkin and TREM2 protein by >40% compared to age-matched controls.
- A PINK1 agonist (e.g., kinetin) will reduce both phospho-tau (Thr231) and phospho-alpha-synuclein (Ser129) in a dual-pathology mouse model (A53T SNCA x APP/PSEN1).
Cross-references: Bridges h-89f2d5ab82 (PINK1/Parkin PD-focused) and h-7eaed928c5 (TREM2 AD-focused).
Evidence for (5)
Spautin-1 promotes PINK1-PRKN-dependent mitophagy and improves associative learning capability in an alzheimer disease animal model.
PINK1-PRKN mediated mitophagy: differences between in vitro and in vivo models.
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.
Targeting mitophagy in neurodegenerative diseases.